AIDS-related Kaposi's sarcoma

AIDS-related Kaposi's sarcoma
Name	AIDS-related Kaposi's sarcoma
Field	Oncology, Infectious disease (medical specialty)
Symptoms	Cutaneous lesions, lymphedema, visceral involvement
Complications	Organ dysfunction, Opportunistic infection
Causes	Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in HIV/AIDS
Risks	Advanced HIV infection, low CD4 count, MSM
Diagnostic method	Biopsy, Histopathology, PCR
Treatment	Antiretroviral therapy, Chemotherapy, Radiation therapy
Medication	Liposomal doxorubicin, Paclitaxel
Prognosis	Variable, dependent on immune reconstitution

AIDS-related Kaposi's sarcoma is an AIDS-defining clinical condition and the most common malignancy occurring in individuals with advanced HIV infection. It is caused by coinfection with Kaposi's sarcoma-associated herpesvirus (KSHV, also known as Human herpesvirus 8) in the setting of profound immune suppression. The disease is characterized by the proliferation of spindle cells and aberrant blood vessel formation, leading to lesions that can involve the skin, mucous membranes, lymph nodes, and internal organs. Prior to the advent of effective Antiretroviral therapy, it was a leading cause of morbidity and mortality in the AIDS pandemic.

Epidemiology and risk factors

The incidence of this malignancy surged dramatically during the early years of the HIV/AIDS epidemic, particularly among Men who have sex with men in North America and Europe. It remains highly prevalent in regions where both HIV-1 and Kaposi's sarcoma-associated herpesvirus are endemic, such as Sub-Saharan Africa. The primary risk factor is a low CD4 lymphocyte count, typically below 200 cells/µL, indicating severe immunosuppression. Other risk factors include older age at HIV diagnosis, lack of Antiretroviral therapy, and Male sex. The prevalence has declined substantially in high-income countries following the widespread introduction of Highly Active Antiretroviral Therapy in the mid-1990s, though it persists as a significant public health challenge in resource-limited settings.

Pathogenesis and virology

The essential etiologic agent is Kaposi's sarcoma-associated herpesvirus, a gammaherpesvirus first identified by Yuan Chang and Patrick S. Moore in 1994. The virus establishes latent infection in endothelial lineage cells and expresses viral oncogenes such as LANA, vFLIP, and vCyclin. These proteins promote cell survival, proliferation, and angiogenesis by dysregulating critical cellular pathways including the p53 and Retinoblastoma protein tumor suppressor networks. In the context of HIV-induced immunosuppression, loss of immune control over KSHV allows for viral reactivation and increased viral load. Furthermore, the HIV-1 Tat protein acts as a cofactor, stimulating inflammatory cytokine production and enhancing the angiogenic and growth-promoting effects of KSHV.

Clinical presentation and diagnosis

Classic presentation involves cutaneous lesions ranging from faint macules to raised plaques or nodules, often with a violaceous, brown, or red hue. These are frequently found on the face, genitals, and lower extremities. Mucosal involvement may affect the oral cavity (particularly the hard palate) and the Gastrointestinal tract. Lymphedema is a common and debilitating complication. Visceral disease can involve the lungs, manifesting as dyspnea and hemorrhage, or the Gastrointestinal tract, causing obstruction or bleeding. Diagnosis is confirmed by Biopsy of a lesion, with Histopathology revealing characteristic spindle cells, extravasated red blood cells, and hyaline droplets. Detection of KSHV DNA via PCR in tissue or blood supports the diagnosis.

Treatment and management

The cornerstone of management is the initiation or optimization of combination Antiretroviral therapy to restore CD4 counts and suppress HIV replication. Immune reconstitution often leads to regression of early lesions. For progressive, symptomatic, or visceral disease, systemic chemotherapy is indicated. First-line agents include Liposomal doxorubicin and Liposomal daunorubicin. Paclitaxel is commonly used as second-line therapy. Localized disease may be treated with Radiation therapy, Intralesional chemotherapy (e.g., Vinblastine), or Cryotherapy. For isolated cosmetic lesions, Laser surgery or surgical excision may be considered. Management of concurrent opportunistic infections and supportive care for symptoms like Lymphedema are integral components.

Prognosis and outcomes

Prognosis is intrinsically linked to the degree of Immunosuppression and the extent of the malignancy. The introduction of Antiretroviral therapy has transformed the disease course, dramatically improving survival. A poor prognosis is associated with widespread visceral involvement, especially Pulmonary Kaposi sarcoma, and the presence of other AIDS-defining illnesses. The TNM staging system is less predictive than the AIDS Clinical Trials Group staging system, which incorporates tumor extent, Immune system status (CD4 count), and the presence of systemic illness. With effective treatment, many patients achieve complete clinical remission, though the risk of recurrence persists if immunosuppression recurs.

Prevention and public health

Primary prevention focuses on avoiding infection with both HIV and Kaposi's sarcoma-associated herpesvirus through Safer sex practices and use of condoms. For individuals living with HIV, the most effective preventive measure is early and sustained treatment with Antiretroviral therapy to maintain a high CD4 count, thereby preventing the immune dysfunction that permits KSHV-driven oncogenesis. Public health strategies include expanding access to HIV testing and treatment globally, as championed by programs like the U.S. President's Emergency Plan for AIDS Relief and the World Health Organization. Ongoing research into a Vaccine against KSHV and screening for KSHV in high-risk populations are areas of active investigation.

Category:HIV/AIDS Category:Oncology Category:Infectious diseases